Breaking Immune Tolerance to the Prion Protein Using Prion Protein Peptides Plus Oligodeoxynucleotide-CpG in Mice

Journal of Immunology

Volumn 172, Issue 9, 2004, Pages 5168-5174

  Rosset, Martine Bruley ^a,b   Ballerini, Clara ^a   Gregoire, Sylvie ^a   Metharom, Pat ^a   Carnaud, Claude ^a   Aucouturier, Pierre ^a  

^a INSERM   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; OLIGODEOXYNUCLEOTIDE; PEPTIDE DERIVATIVE; PRION PROTEIN; PROTEIN ANTIBODY; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL SURFACE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE RELEASE; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HOST CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPH NODE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN MOTIF; SPLEEN; T LYMPHOCYTE ACTIVATION; WILD TYPE;

EID: 2142706520     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.9.5168     Document Type: Article

References (43)

1. Prusiner, S. B. 1998. Prions. Proc. Natl. Acad. Sci. USA 95:13363.
2. Prusiner, S. B., M. R. Scott, S. J. De Armond, and F. E. Cohen. 1998. Prion protein biology. Cell 93:337.
3. Aucouturier, P., and C. Carnaud. 2002. The immune system and prion diseases: a relationship of complicity and blindness. J. Leukocyte Biol. 72:1073.
4. Porter, D. D., H. G. Porter, and N. A. Cox. 1973. Failure to demonstrate a humoral immune response to scrapie infection in mice. J. Immunol. 111:1407.
5. Kascsak, R. J., R. Rubenstein, P. A. Merz, M. Tonna-DeMasi, R. Fersko, R. I. Carp, H. M. Wisniewski, and H. Diringer. 1987. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J. Virol. 61:3688.
6. Williamson, R. A., D. Peretz, N. Smorodinsky, R. Bastidas, H. Serban, I. Mehlhorn, S. J. DeArmond, S. B. Prusiner, and D. R. Burton. 1996. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc. Natl. Acad. Sci. USA 93:7279.
7. o/o mice. Mol. Med. 2:725.
8. Rubenstein, R., R. J. Kascsak, M. Papini, R. Kascsak, R. I. Carp, G. LaFauci, R. Meloen, and J. Langeveld. 1999. Immune surveillance and antigen conformation determines humoral immune response to the prion protein immunogen. J. Neurovirol. 5:401.
9. Souan, L., Y. Tal, Y. Felling, I. R. Cohen, A. Taraboulos, and F. Mor. 2001. Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31:2338.
10. Sigurdsson, E. M., D. R. Brown, M. Daniels, R. J. Kascsak, R. Kascsak, R. Carp, H. C. Meeker, B. Frangione, and T. Wisniewski. 2002. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161:13.
11. Gilch, S., F. Wopfner, I. Renner-Muller, E. Kremmer, C. Bauer, E. Wolf, G. Brem, M. H. Groschup, and H. M. Schatzl. 2003. Polyclonal anti-PrP autoantibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. 278:1852.
12. Schwarz, A., O. Kratke, M. Burwinkel, C. Riemer, J. Schultz, P. Henklein, T. Bamme, and M. Baier. 2003. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. 350:187.
13. White, A. R., P. Enever, M. Tayebi, R. Mushens, J. Linehan, S. Brandner, D. Anstee, J. Collinge, and S. Hawke. 2003. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422:80.
14. Janus, C., J. Pearson, J. McLaurin, P. M. Mathews, Y. Jiang, S. D. Schmidt, M. A. Chishti, P. Horne, D. Heslin, J. French, et al. 2000. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979.
15. Nicoll, J. A., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9:448.
16. Souan, L., R. Margalit, O. Brenner, I. R. Cohen, and F. Mor. 2001. Self prion protein peptides are immunigenic in Lewis rats. J. Autoimmun. 17:303.
17. Bainbridge, J., and B. Walker. 2003. Cell mediated immune responses against human prion protein. Clin. Exp. Immunol. 133:310.
18. Grégoire, S., C. Logre, P. Metharom, F. Loing, S. Chomillier, M. Bruley Rosset, P. Aucouturier, and C. Carnaud. Identification of two immunogenic domains of the prion protein, PrP, which activate class II-restricted T cells and elicit antibody responses against the native molecule. J. Leukocyte Biol. In press.
19. Bendheim, P. E., H. R. Brown, R. D. Rudelli, L. J. Scala, N. L. Goller, G. Y. Wen, R. J. Kascsak, N. R. Cashman, and D. C. Bolton. 1992. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 42:149.
20. Martin, R., D. Jaraquemada, M. Flerlage, J. Richert, J. Whitaker, E. O. Long, D. E. McFarlin, and H. F. McFarland. 1990. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 145:540.
21. Krieg, A. 2003. CpG motifs: the active ingredient in bacterial extracts? Nat. Med. 9:831.
22. Krug, A., S. Rothenfusser, V. Hornung, B. Jahrsdoffer, S. Blackwell, Z. K. Ballas, A. M. Krieg, and G. Hartmann. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31:2154.
23. Krug, A., A. Towarowski, S. Britsch, S. Rothenfusser, V. Hornung, R. Bals, T. Giese, H. Engelmann, S. Endres, A. M. Krieg, and G. Hartmann. 2001. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amount of IL-12. Eur. J. Immunol. 31:3037.
24. Miconnet, I., S. Koenig, D. Speise, A. Krieg, P. Guillaume, J. C. Cerottini, and P. Romero. 2002. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168:1212.
25. Stern, B. V., B. O. Boehm, and M. Tary-Lehmann. 2002. Vaccination with tumor peptide in CpG adjuvant protects via IFN-γ-dependent CD4 cell immunity. J. Immunol. 168:6099.
26. Davila, E., R. Kennedy, and E. Celis. 2003. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 63:3281.
27. + T lymphocytes by immunostimulatory DNA-based vaccines. J. Immunol. 168:4907.
28. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzeky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 374:546.
29. Ballas, Z. K., A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner. 2001. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167:4878.
30. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehman, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper1 (Th1) immunity. J. Exp. Med. 186:1623.
31. Ballas, Z. K., W. L. Rasmussen, and M. A. Krieg. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1840.
32. Lanzavecchia, A. 1983. One out of five peripheral blood lymphocytes is activated to high rate of Ig production by human alloreactive T-cell clones. Eur. J. Immunol. 13:820.
33. Martin-Orozco, E., H. Kobayashi, J. Van Uden, M. D. Nguyen, R. S. Kornbluth, and E. Raz. 1999. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol. 11:1111.
34. Grossmann, M. E., E. Davila, and E. Celis. 2001. Avoiding tolerance to prostatic antigens with subdominant peptide epitopes. J. Immunother. 24:237.
35. Hiroshi, T., L. P. Williams, and B. M. Segal. 2002. Activation of APCs through CD40 or Toll-like receptor-9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169:2781.
36. Kocisco, D. A., S. A. Priola, G. J. Raymond, B. Chesebro, P. T. Landsbury, Jr., and B. Caughey. 1995. Species-specific in cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barriers. Proc. Natl. Acad. Sci. USA 92:3923.
37. Bard, F., R. Barbour, C. Cannon, R. Caretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, et al. 2002. Epitope and isotype specificities of antibodies to β amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA 100:2023.
38. Enari, M., E. Flechsig, and C. Weissmann. 2001. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. USA 98:9295.
39. Peretz, D. R., A. Williamson, K. Kaneko, J. Vergara, E. Leclerc, G. Schmitt-Ulms, I. R. Mehlhorn, G. Legname, M. R. Wormald, P. M. Rudd, et al. 2001. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412:739.
40. Heppner, F. L., C. Musahl, I. Arrighi, M. A. Klein, T. Rulicke, B. Oesch, R. M. Zinkernagel, U. Kalinke, and A. Aguzzi. 2001. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294:178.
41. Sethi, S., G. Lipford, H. Wagner, and H. Kretzschmar. 2002. Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 360:22930.
42. Tal, Y., L. Souan, I. R. Cohen, Z. Meiner, A. Taraboulos, and F. Mor. 2003. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J. Neurosci. Res. 71:286.
43. Thoelen, S., P. Van Damme, C. Mathei, G. Leroux-Roels, I. Desombere, A. Safary, P. Vandepapeliere, M. Slaoui, and A. Meheus. 1998. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16:708.